Your browser doesn't support javascript.
loading
Larotrectinib versus infigratinib for adult patients with both glioma and tyrosine kinase alterations after failure of initial therapies: Efficacy and safety analysis.
Chen, Yufang; Ma, Jian; Gao, Qianqian; Gai, Yu; Sun, Yichi; Wang, Meihua.
Afiliação
  • Chen Y; Department of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China.
  • Ma J; Department of Oncology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China.
  • Gao Q; Department of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China.
  • Gai Y; Department of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China.
  • Sun Y; Department of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China.
  • Wang M; Department of Pathology, Changzhou Tumor Hospital, Changzhou, Jiangsu, China. Electronic address: wangmeihua1234@suda.edu.cn.
Clinics (Sao Paulo) ; 79: 100329, 2024.
Article em En | MEDLINE | ID: mdl-38330791
ABSTRACT

OBJECTIVES:

To compare the efficacy and safety of larotrectinib with those of infigratinib in adult glioma patients with tyrosine kinase alterations.

METHODS:

Patients received oral infigratinib 125 mg (IN cohort, n = 125) or oral larotrectinib (LB cohort, n = 105) until unacceptable toxicity or disease progression.

RESULTS:

Duration of treatment was longer in the LB cohort than in the IN cohort (8 [9.5-6.25] months vs. 5.5 [6-5.25] months, p < 0.0001). Patients with partial responses (p = 0.0424) and overall survival (p = 0.03) were higher in the IN cohort than those in the LB cohort. The number of patients with disease progression was higher in the LB cohort (p = 0.0015). All the patients reported diarrhea, fatigue, vomiting, constipation, and decreased appetite. Patients in the IN cohort reported hyperphosphatemia, hyperlipasemia, stomatitis, dry skin, alopecia, dyspepsia, onycholysis, palmar-plantar erythrodysesthesia, nail disorders, and dry eyes. Patients in the LB cohort reported upper respiratory tract infections, pyrexia, cough, anemia, bacterial/viral infections, conjunctivitis, urinary tract infections, headaches, ataxia, dizziness, and muscle tremors. A total of 30 (24 %) and 40 (38 %) patients from the IN and the LB cohorts died at the follow-up of 18 months (p = 0.03). Patients who received bevacizumab initial therapy had higher overall survival (p = 0.048).

CONCLUSIONS:

Infigratinib has higher efficacy and overall survival than larotrectinib but has higher adverse effects in the management of both glioma and tyrosine kinase alterations after failure of initial therapies. Initial bevacizumab therapy is associated with a higher overall survival.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirazóis / Pirimidinas / Proteínas Tirosina Quinases / Glioma Limite: Adult / Humans Idioma: En Revista: Clinics (Sao Paulo) Assunto da revista: MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Pirazóis / Pirimidinas / Proteínas Tirosina Quinases / Glioma Limite: Adult / Humans Idioma: En Revista: Clinics (Sao Paulo) Assunto da revista: MEDICINA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos